Q-omics provides the consensus-scored PDE4DIPP1 profile across patient tissues and cancer cell-line models. PDE4DIPP1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PDE4DIPP1 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, PDE4DIPP1 RNA expression shows 14,846 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, BRCA, and ACC as cancer lineages where PDE4DIPP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE4DIPP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE4DIPP1 survival associations across molecular data types. PDE4DIPP1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE4DIPP1 RNA expression–survival associations across cancer types. High PDE4DIPP1 expression shows unfavorable associations in ACC, COAD and LUSC, but favorable associations in HNSC, UCS and THCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PDE4DIPP1 RNA expression.
This table summarizes PDE4DIPP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for PDE4DIPP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE4DIPP1 shows lower tumor expression in BRCA, COAD, KICH, PRAD and UCEC and higher tumor expression in KIRP. The BRCA box plot shows higher PDE4DIPP1 RNA expression in normal versus tumor tissue (log2 FC = −0.066, t-test p < 0.001).
This table shows molecular features associated with PDE4DIPP1 in patient tissues and cancer cell lines. In patient samples, PDE4DIPP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
